Please login to the form below

Not currently logged in

New executive appointments at Synergy Vision

Eileen Gallagher and Karine Henderson take on new leadership roles

Synergy Vision has appointed Eileen Gallagher to the role of chief operating officer.

Gallagher has worked at Synergy Vision since its inception, having been part of the founding team.

During her time at Synergy, Gallagher (pictured left) has worked as both a director and managing director.

Prior to this, she worked at GlaxoSmithKline for a period of 11 years in a number of roles.

Also joining the executive team at Synergy Vision is Karine Henderson, who will take on the role of managing director.

Before taking on the managing director position, Henderson (pictured right) worked as director of medical strategy at Synergy, having joined just over one year ago.

She has over 20 years of healthcare communication experience, across both the client and agency settings.

“This new structure allows us to continue our growth plans over the next five years.  2020 has been challenging but allowed our team to innovate and find new ways to deliver for our clients whilst continuing to grow," said Ffyona Dawber, chief executive officer and founder of Synergy Vision.

"I feel confident with our plans to develop the company and take Synergy Vision to the next level, and I am delighted to have such and esteemed senior team to take us on the next step in our journey," he added.

Article by
Lucy Parsons

15th January 2021

From: Marketing


COVID-19 Updates and Daily News

Featured jobs


Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Securing a future for telehealth with immersive market research insights...